Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Rectal Neoplasms 13Breast Neoplasms 12Colorectal Neoplasms 11Colonic Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia 9Carcinoma, Non-Small-Cell Lung 9Leukemia, Myeloid, Acute 8Carcinoma, Renal Cell 8Prostatic Neoplasms 7Lung Neoplasms 7Kidney Neoplasms 7Multiple Myeloma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Gliosarcoma 6Glioblastoma 6Esophageal Neoplasms 6Congenital Abnormalities 6Stomach Neoplasms 5Melanoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Myelodysplastic Syndromes 4Lymphoma, Large-Cell, Immunoblastic 4

Interventions

Doxorubicin 15Cyclophosphamide 9Exercise 8Dexrazoxane 8Razoxane 6Carvedilol 6Vincristine 4Trastuzumab 4Radiotherapy 4Filgrastim 4Docetaxel 4Methotrexate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Echocardiography 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Silymarin 2Prednisone 2Paclitaxel 2Neoadjuvant Therapy 2Leucovorin 2Ivabradine 2High-Intensity Interval Training 2Epirubicin 2Electrocardiography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cardiotoxicity × Gene Expression Profiling × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡